Evidence map›Paper›PMID 36713681›Full record

ArticleBlood cell therapy2022

Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: A report of the Activity Survey 2017 from APBMT.

Minako Iida, Kaiyan Liu, Xiao Jun Huang, Wu Depei, Yachiyo Kuwatsuka, Joon Ho Moon, Anthony Dodds, Leonie Wilcox, Bor-Sheng Ko, Amir Ali Hamidieh and 16 more

Abstract read
In one paragraph

Article in Blood cell therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Minako IidaDepartment of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan.
Kaiyan LiuDepartment of Hematology, Peking University Institute of Hematology, Beijing, China.
Xiao Jun HuangDepartment of Hematology, Peking University Institute of Hematology, Beijing, China.
Wu DepeiDepartment of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Yachiyo KuwatsukaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Joon Ho MoonDivision of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Anthony DoddsSt. Vincent's Pathology, St. Vincent's Health Network, Sydney, and Australasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia.
Leonie WilcoxAustralasian Bone Marrow Transplant Recipient Registry (ABMTRR), Sydney, Australia.
Bor-Sheng KoDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Amir Ali HamidiehPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Kim Wah HoDepartment of Hematology, Hospital Ampang, Ampang Selangor, Malaysia.
Artit UngkanontChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.
Aloysius HoDepartment of Haematology, Singapore General Hospital, Singapore, Singapore.
Tasneem FarzanaDepartment of Clinical Haematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan.
Joycelyn SimDepartment of Medicine, Queen Mary Hospital, Hong Kong.
Huynh Van ManStem Cell Transplantation Department, Blood Transfusion and Hematology Hospital, Ho Chi Minh, Vietnam.
Mafruha AkterBone marrow transplant unit, Department of Hematology, Dhaka Medical College and Hospital, Dhaka, Bangladesh.
Prasad AbeysingheDepartment of Oncology, National Cancer Institute, Maharagama, Sri Lanka.
Marjorie Rose BravoSt Luke's Medical Center Quezon City, IM Hematology/Blood and Marrow Transplant, Quezon, the Philippines.
Aye Aye GyiDepartment of Clinical Haematology, North Okkalapa General Hospital, Yangon, Myanmar.
Bishesh Sharma PoudyalCivil Service Hospital, Clinical Hematology and Bone Marrow Transplant Unit, Kathmandu, Nepal.
Khishigjargal BatshkhBone and Marrow transplantation team, Hematology Department, National First Central Hospital of Mongolia, Ulaanbaatar, Mongolia.
Alok SrivastavaDepartment of Haematology, Christian Medical College Hospital, Vellore, India.
Shinichiro OkamotoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Nagakute, Japan.
Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Asia-Pacific Blood and Marrow Transplantation Group (APBMT) has been conducting annual surveys on the activity of hematopoietic stem cell transplants since 2007. The APBMT Data Center collected the following data in 2017. A total of 21,504 transplants were registered from 733 transplant centers of 20 countries/regions in the Asia-Pacific (AP) region. Five countries/regions comprised 89.4% of all transplants - China (6,979), Japan (5,794), South Korea (2,626), India (2,034), and Australia (1,789). The number of centers in these five countries/regions also comprised 88.9% of all centers: Japan (373), China (123), India (66), Australia (45), and South Korea (44). The overall ratio between autologous and allogeneic transplants was 37.0% and 63.0%, respectively, but the ratios varied significantly among countries/regions. Autologous transplants have surpassed allogeneic transplants in Thailand, Australia, Vietnam, New Zealand, Singapore, and Iran. In contrast, the proportion of allogeneic transplants comprised over 70% of all transplants in Pakistan, China, and Hong Kong. These ratios were compared by the Data Center among countries/regions that performed more than 50 transplants. The proportion of related and unrelated transplants also differed among countries/regions. The number of unrelated transplants was more than related ones in Japan (2,551 vs. 1,202) and Australia (329 vs. 291), whereas more than 80% of all transplants were related transplants in Malaysia (90.9%), India (89.5%), Iran (87.2%), Vietnam (85.7%), China (80.9%), and Thailand (80.6%). All transplant activities were related transplants in Pakistan, the Philippines, Myanmar, and Nepal, and no allogeneic transplants were performed in Bangladesh and Mongolia. Regarding the indications for transplants, acute myeloid leukemia (AML) was the most common disease for allogeneic transplant (4,759, 35.1% of allogeneic transplants), while plasma cell disorder (PCD) was the most common disease for autologous transplant (3,701, 27.3% of all autologous transplants). Furthermore, the number of transplants for hemoglobinopathy has steeply increased in this region compared with the rest of disease indications (677, 3.1% of all transplants). APBMT covers a broad area globally, including countries/regions with diverse disease distribution, development of HSCT programs, population, and economic power. Consistent and continuous activity surveys considering those elements in each country/region revealed the HSCT field's diverse characteristics and background factors in this region.

Indexed as

Asia-Pacific regiondisease indicationhematopoietic stem cell transplant

Identifiers

PMID36713681
PMCPMC9873430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.